The Centers for Disease Control and Prevention (CDC) announced the death of an individual who had been hospitalized with severe avian influenza A (H5N1).
On Tuesday, just one day after the first reported bird flu fatality in the United States, Moderna’s stock price surged by over 10%, leading to gains in the S&P 500 index.
Moderna is actively developing a vaccine for H5N1.
The CDC commented that the outcome was “not unexpected,” given the known potential of these viruses to cause severe illness and death.
They also reported that since 2022, the U.S. has recorded 67 confirmed cases of H5N1 avian influenza, 66 of which occurred after 2024.
Although Moderna’s stock has experienced a steep decline over the past year, it climbed 13.31% on this news, closing at $48.23.
Most Commented